Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence-Reference-Cited by-同舟云学术

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Published:2016-07 Issue:7 Volume:27 Page:1241-1248
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mittendorf E.A.,Ardavanis A.,Symanowski J.,Murray J.L.,Shumway N.M.,Litton J.K.,Hale D.F.,Perez S.A.,Anastasopoulou E.A.,Pistamaltzian N.F.,Ponniah S.,Baxevanis C.N.,von Hofe E.,Papamichail M.,Peoples G.E.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/7/1241/6676883/mdw150.pdf

Reference20 articles.

1. The E75 HER2/neu peptide vaccine;Mittendorf;Cancer Immunol Immunother,2008

2. Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02;Peoples;Clin Cancer Res,2008

3. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy;Knutson;Cancer Immunol Immunother,2005

4. Augmenting T helper cell immunity in cancer;Knutson;Curr Drug Targets Immune Endocr Metabol Disord,2005

5. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine;Disis;Clin Cancer Res,1999

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

2. Recent Advances in Immunotherapy for Breast Cancer: A Review;Breast Cancer: Targets and Therapy;2024-08

3. Immunotherapy in Breast Cancer;International Journal of Molecular Sciences;2024-07-09

4. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer;Molecular Cancer;2024-05-07

5. Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies;Journal of Clinical Medicine;2024-03-24